tolebrutinib
sanofi
['tolebrutinib', 'multiple sclerosis']
over 2 years of treatment with tolebrutinib was safe and kept relapse rates low for multiple sclerosis patients in a phase 2 trial extension. #aan2023 #news 
We exist to bring you science, research and clinical news about MS. We are a free digital publication dedicated to the patient community.